MK0954A-264 Filter Study (0954A-264)(COMPLETED)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

274 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-12-01

Study Completion Date

2005-06-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the blood pressure lowering efficacy, safety and tolerability of a combination drug to a single drug taken once daily in patients with uncontrolled blood pressure following a 4-week filter on the single therapy product.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)

NCT01431508

Hypertension

COMPLETED PHASE4

A Study to Investigate the Magnitude and Duration of Response of MK0954 Compared to Placebo in Patients With Hypertension (0954-021)(COMPLETED)

NCT00886600

Hypertension

COMPLETED PHASE3

MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)

NCT01307046

Hypertension

COMPLETED PHASE3

MK-0954E Study in Participants With Hypertension (MK-0954E-357)

NCT01302691

Hypertension

COMPLETED PHASE3

Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)

NCT00140959

Hypertension

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild to Severe Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks

Intervention Type DRUG

losartan / Duration of Treatment: 6 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients with mild to severe hypertension (SiDBP 90-120 mmHg)

Exclusion Criteria

* Systolic BP \> 200 mmHg
* Secondary or malignant hypertension
* Taking more than 2 antihypertensive medications
* Hypertension induced by oral contraceptives
* Hx of cerebral vascular accident within 6 months
* Hx of angina, myocardial infarction, PCI, CABG, or decompensated CHF within 6 months
* Clinically significant AV conduction disturbance or potentially life threatening ventricular arrhythmias, valvular disease, cardiomyopathy, unexplained syncope
* History of angioedema
* Sensitivity to AII receptor antagonists or HCTZ, nephrotic syndrome,single kidney function
* Pregnancy or lactation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No